SCHEMBL6038894

SCHEMBL6038894

Cc1ccc(S(=O)(=O)Nc2ncc(-c3cccc(-c4ccccc4)c3)nc2OCc2cccnc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 2/20 0.49
POLB P06746 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
SCN9A Q15858 1/20 0.43
KCNA5 P22460 2/20 0.43
ADAMTS4 O75173 1/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
AR P10275 1/20 0.42
HTT P42858 1/20 0.42
MAPT P10636 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
LMNA P02545 2/20 0.41
NAMPT P43490 2/20 0.41
NMT1 P30419 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038479 0.94 POLB (0.49) CCR4POLBSMN1; SMN2SCN9AKCNA5
SCHEMBL6038816 0.94 CCR4 (0.50) CCR4POLBSMN1; SMN2SCN9AKCNA5
SCHEMBL6038976 0.93 CCR4 (0.50) CCR4POLBSMN1; SMN2SCN9AKCNA5
SCHEMBL6038968 0.91 CCR4 (0.47) CCR4SMN1; SMN2SCN9AKCNA5ADAMTS4
SCHEMBL6038593 0.90 CCR4 (0.48) CCR4POLBSMN1; SMN2SCN9AKCNA5
SCHEMBL6038463 0.90 CCR4 (0.48) CCR4POLBSMN1; SMN2SCN9AKCNA5
SCHEMBL6038813 0.90 CCR4 (0.52) CCR4POLBSMN1; SMN2SCN9AKCNA5
SCHEMBL6038792 0.90 CCR4 (0.47) CCR4SMN1; SMN2SCN9AMEN1KMT2A
SCHEMBL6038775 0.90 CCR4 (0.47) CCR4POLBSMN1; SMN2SCN9AKCNA5
SCHEMBL6038707 0.89 CCR4 (0.47) CCR4POLBSMN1; SMN2SCN9AKCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 CCR4 1/4885POLB 4738/4885SMN1; SMN2 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.